Can Leukotriene Modifiers and Mast Cell Stabilizers Decrease the Fatal Outcomes of Coronavirus?

Human coronavirus infections can induce severe pulmonary pathologies but also typical symptoms of infectious diseases, including inflammation, high fever, cough and organ failures that might be fatal. Some of the immune cells (mast cells), which are located in the submucosa of the pulmonary tract, attack primarily to Coronavirus.^1-4 First, the virus activates mast cells and then certain chemical compounds are generated against the pathogen. Here, we develop a new idea that inflammation in patients with COVID-19 may be mitigated by both leukotriene modifiers and mast cell stabilizers. COVID-19 is frequent and the most of people’s nasal secretions contain specific antibodies to decrease the infectivity of the Coronavirus. Cell-mediated immunity with allergy have not been studied well-enough in the literature, but it may play a crucial role in pathogenesis. While working to find a novel drug for COVID-19 or for the prevention of fatal coronavirus infections with a vaccine for future outbreaks, the discovering re-purposed both leukotriene modifiers and mast cell stabilizers to attenuate the effect of virüs to some extent may be achieved by new clinical trials. We must also prevent those of patients who are under threat of COVID-19 induced cytokine storms, which is often fatal among patients with COVID-19.² Physicians must first be aware of the possibility of both leukotriene modifiers and mast cell stabilizers, then make the diagnosis. With a proactive manner in medicine, we must specifically find a solution to the infected patients with overly active immune responses beforehand because of the outcomes from the overactive immune response can be deadly. One of the most important mechanisms underlying the deterioration of disease is cytokine storm.²